Dignitana AB Taps oneservice as Service Provider in Europe

Dignitana AB, manufacturer of The DigniCap® Scalp Cooling System, announces today that it has partnered with oneservice, a global provider of specialty technical services, to provide service and maintenance to facilities offering DigniCap in Europe.

As part of Dignitana’s ongoing commitment to high-quality customer service, oneservice will handle installation, maintenance, technical support and repairs for customers in Europe. Facilities in the region will be transitioned to oneservice effective 1 March 2019.

“Delivering accessible and rapid-response customer service continues to be a top priority for our company,” said William Cronin, CEO of Dignitana. “oneservice —with their dedicated team of industry experts and abundance of state-of-the-art resources—is a valuable partner in supporting the DigniCap product as we work to efficiently expand our services around the world.”

In April 2018, Dignitana acquired the management of DigniCap installations at 70 medical facilities in 11 European countries from Sysmex. At the close of the fourth quarter DigniCap distribution in the region had grown to 86 locations.

“oneservice is proud to partner with Dignitana in servicing a market with enormous potential,” said Matthias Raquet, CEO of oneservice. “Our proven history of providing innovative solutions for medical device, diagnostics and life science companies will help us to truly take Dignitana’s work in Europe to new levels. We look forward to a long and mutually beneficial partnership.”  

Hailed internationally as a life-changing medical advancement for cancer patients, The DigniCap Scalp Cooling System was invented in 1999 by a Swedish Oncology nurse and has been available in Europe since 2001. DigniCap the first scalp cooling system to be cleared by the FDA in 2015 for use by breast cancer patients and the first to be cleared in July 2017 for use by patients with solid tumor cancers. With a 66.3 percent success rate, the device achieved clinically superior results in the pivotal trial which led to FDA clearance.

There are nearly 3.7 million new cancer diagnoses in Europe per year (WHO) and breast cancer is the most common cancer in European women with approximately 500,000 new diagnoses per year (European Breast Cancer Coalition).